How to Value a Sleep Lab or Sleep Center

Sleep medicine is a niche within healthcare that most M&A advisors don't understand well, which means sleep center owners often get undervalued in transactions. The business model is highly specific — it sits at the intersection of diagnostics, DME, and chronic disease management — and the valuation drivers are unlike anything in general medical practice.

I've worked on sleep center transactions ranging from single-location diagnostic labs to multi-site sleep medicine practices with integrated CPAP/DME operations. The valuation spread is significant, and most of it comes down to how the business is positioned against the single biggest disruption in the industry: the shift from in-lab polysomnography to home sleep testing.

The Multiple Range: 4-8x EBITDA

Sleep diagnostic centers and sleep medicine practices trade at 4-8x EBITDA in the current market. That range is wide because the industry is bifurcating: traditional in-lab-only sleep centers are under pressure, while integrated sleep practices that combine diagnostics, treatment, and DME are thriving.

At 4-5x, you're looking at a standalone sleep lab — 4-8 beds, doing primarily in-lab polysomnography (PSG), billing $1,200-$2,500 per study depending on payer mix, but with declining referral volume as more physicians order home sleep tests instead. Revenue is flat or declining, and the business is essentially a diagnostic facility with no treatment revenue.

At 6-8x, the business is an integrated sleep medicine practice: diagnostic testing (both in-lab PSG and home sleep testing), board-certified sleep physician consultations, CPAP/BiPAP device management, mask fitting and supply fulfillment, and potentially oral appliance therapy. These practices generate diversified revenue, have recurring patient relationships, and can capture the full value chain from diagnosis through ongoing treatment.

Study Volume and Capacity Utilization

For in-lab sleep centers, the core metric is studies per bed per month. A sleep lab with 6 beds can theoretically run 180 studies per month (one study per bed, 30 nights). In practice, utilization of 60-75% is good, meaning 108-135 studies per month for a 6-bed lab.

Each in-lab PSG study generates $1,200-$2,500 in technical fees, plus $200-$400 in professional (physician interpretation) fees. At 120 studies per month with a blended rate of $1,500, that's $180K/month or $2.16M annually from the lab alone. EBITDA margins for well-run in-lab operations typically run 25-35%, producing $540K-$756K in EBITDA.

Home sleep testing (HST) is different economics. The device (WatchPAT, Alice NightOne, or similar) costs $2,000-$5,000 to purchase, can be reused 50-100+ times, and insurance reimburses $200-$500 per study. The margin per study is lower, but the volume capacity is essentially unlimited — you're not constrained by bed count. A practice doing 200+ HSTs per month alongside 80-100 in-lab studies has a much more defensible revenue model than one doing only in-lab PSGs.

Payer Mix Is Make-or-Break

Sleep center reimbursement varies more by payer than almost any other healthcare service. The spread between commercial insurance and Medicare for the same in-lab PSG can be 3-4x:

• Commercial insurance: $1,800-$2,500 per in-lab PSG (technical + professional)
• Medicare: $600-$900 per in-lab PSG (and declining — CMS has been ratcheting down sleep study reimbursement for years)
• Medicaid: $400-$700 per study, with significant state-by-state variation

A sleep center with 60%+ commercial payer mix is in a fundamentally different financial position than one that's 70% Medicare. Buyers model this explicitly — the same 100-study-per-month lab can produce $200K/month with a commercial-heavy mix or $80K/month with a Medicare-heavy mix. That 2.5x revenue difference flows directly to EBITDA and valuation.

The trend in payer mix is also critical. If commercial insurers in your market are increasingly requiring home sleep tests before authorizing in-lab studies (which many are), your in-lab commercial volume may be eroding. Buyers will look at 36-month payer mix trends, not just the current snapshot.

AASM Accreditation

Accreditation by the American Academy of Sleep Medicine is not legally required in most states, but it's become a de facto standard. Many commercial insurers require AASM accreditation for in-network contracting, and CMS requires it for Medicare reimbursement of in-lab studies.

An AASM-accredited center has met standards for staffing (registered polysomnographic technologists), equipment, physician oversight, quality assurance, and facility design. The accreditation process takes 6-12 months and involves an on-site inspection.

For valuation, AASM accreditation is table stakes for serious buyers. A non-accredited center may still operate and bill some payers, but the buyer universe shrinks dramatically, and the multiple reflects that — typically 3-4x EBITDA at best.

The HST Disruption and How to Navigate It

Home sleep testing is the single most important trend in sleep medicine valuation. HST devices have become more accurate, less expensive, and more widely accepted by payers. Many insurers now require HST as a first-line diagnostic tool, reserving in-lab PSG for cases where HST is inconclusive or the patient has complex comorbidities.

For traditional in-lab-only sleep centers, this is an existential threat. Study volumes at standalone labs have declined 20-40% over the last five years in many markets. Centers that haven't adapted are seeing their businesses slowly compress.

The centers thriving in this environment have adapted by integrating HST into their service model — they do both, routing appropriate patients to the more cost-effective modality while reserving in-lab capacity for complex cases that genuinely need it. This hybrid model actually improves margins: HST costs less to administer, the physician still interprets the results, and the practice captures the downstream treatment (CPAP setup, follow-up management).

Buyers explicitly evaluate where a sleep center sits on the HST adoption curve. A center doing 50%+ of its diagnostics via HST is better positioned than one still relying entirely on in-lab studies. The former has adapted to the market; the latter is fighting it.

The CPAP/DME Integration Premium

This is where the real valuation upside lives. A sleep center that diagnoses obstructive sleep apnea and then also supplies the CPAP device, masks, tubing, and replacement supplies captures a recurring DME revenue stream that can equal or exceed the diagnostic revenue.

The economics: a CPAP setup generates $800-$1,500 in initial equipment revenue (device + mask + accessories). Then, masks and supplies need replacement every 3-6 months, generating $200-$400 per patient per resupply cycle. A practice managing 1,000 active CPAP patients with a 60% resupply compliance rate generates $120K-$240K annually in recurring supply revenue — high-margin, predictable, and independent of new patient acquisition.

Sleep centers with integrated DME operations command 1-2 additional turns of EBITDA multiple compared to diagnostic-only facilities. The recurring nature of CPAP supply revenue is exactly what buyers — particularly PE-backed platforms — are looking for. It transforms a cyclical diagnostic business into one with predictable recurring revenue.

Physician Medical Director Relationship

Most sleep centers operate under a medical director — a board-certified sleep medicine physician who oversees clinical operations, interprets studies, and provides the medical supervision required by regulators and payers. The structure of this relationship is critical to valuation.

If the medical director is the owner and sole physician, you have the same provider-dependency problem seen in any medical practice. When that physician leaves, referral relationships, payer contracts, and clinical operations are all at risk.

The better structure for valuation: a medical director under a long-term (3-5 year) employment or professional services agreement who is committed to staying through and beyond the transaction. Multiple sleep physicians on staff, with the ability to rotate interpretation duties, is even stronger. Board-certified sleep medicine physicians aren't as scarce as some other specialties, but replacing one still takes 3-6 months and disrupts referral patterns.

Who Buys Sleep Centers

The buyer landscape for sleep centers is consolidating. Regional sleep platforms backed by PE are the most active acquirers — companies like Ognomy, Singular Sleep, and various regional players are building multi-site sleep medicine platforms. They pay 5-8x EBITDA for integrated practices that fit their model. Hospital systems acquiring sleep centers to keep referral revenue in-network are also active, though they tend to move slowly. DME companies looking to vertically integrate upstream (from equipment supply into diagnosis) represent an emerging buyer category. Pulmonology groups adding sleep medicine as a service line round out the buyer pool for smaller centers.

The Bottom Line

Sleep medicine is at an inflection point. The standalone in-lab sleep center model is under structural pressure from HST adoption, Medicare reimbursement compression, and payer requirements. Centers that have adapted — integrating HST, adding CPAP/DME, and building around a comprehensive sleep medicine practice model — are commanding premium multiples and attracting sophisticated buyers.

If you're running a sleep center and thinking about an exit, the playbook is clear: integrate HST and DME if you haven't already, diversify your payer mix toward commercial, and secure your medical director relationship with a long-term agreement. Those three moves can shift your valuation from 4x to 7-8x EBITDA — a difference of millions on a typical sleep center transaction.